Mustak Ayub

Dr. Mustak Ayub


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2020 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMustak Ayub
Mustak Ayub
SARS-CoV-2, the novel coronavirus behind COVID-19 pandemic is acquiring new mutations in its genome. Although some mutations provide benefits to the virus against human immune response, a number of them may result in their reduced pathogenicity and virulence. By analyzing more than 3000 high-coverage, complete genome sequences deposited in the GISAID database, here I report a unique 28881-28883:GGG>AAC trinucleotide-bloc mutation in the SARS-CoV-2 genome that results in two sub-strains, described here as SARS-CoV-2g (28881-28883:GGG genotype) and SARS-CoV-2a (28881-28883:AAC genotype). Computational analysis and literature review suggest that this bloc mutation would bring 203-204:RG(arginine-glycine)>KR(lysine-arginine) amino acid changes in the nucleocapsid (N) protein affecting the SR (serine-arginine)-rich motif of the protein, a critical region for the transcription of viral RNA and replication of the virus. Thus, 28881-28883:GGG>AAC bloc-mutation is expected to modulate the pathogenicity of the SARS-CoV-2. Remarkably, SARS-CoV-2g and SARS-CoV-2a strains can be linked with the heterogeneity of COVID-19 cases across different regions within and between countries by analyzing existing data. Sequence analysis suggests that severely affected cities, such as Milan, Lombardy, New York, Paris have the predominant presence of SARS-CoV-2g strains, whereas less affected places like Abruzzo, Lyon, Valencia have a relatively higher presence of SARS-CoV-2a, an indication that the latter strain may contribute to the reduced cases of COVID-19. A similar relationship is observed when Netherlands, Portugal are compared with Spain, France and Germany. These analyses suggest that the SARS-CoV-2 has already evolved into a less infective SARS-CoV-2a affecting COVID-19 cases in different regions. The time a country or region needs to acquire SARS-CoV-2a strains may be indicative to the time it would need to overcome the peak of the COVID-19 cases. To confirm these assumptions, prompt retrospective and prospective epidemiological studies should be conducted in different countries to understand the course of pathogenicity of the SARS-CoV-2a and SARS-CoV-2g. Potential drugs can be designed targeting 28881-28883 region of the N protein to modulate virus pathogenicity.

28 December 2023 in Bioresearch Communications
Verified
Journal Article
Open access
PDF file
AAAbdul Aziz
Abdul Aziz
NKNabiha Tasneem Khan
Nabiha Tasneem Khan
WKWaqar Ahmed Khan
Waqar Ahmed Khan
MAMustak Ayub
Mustak Ayub
SYSabina Yeasmin
Sabina Yeasmin
Thalassemia is one of the most common genetic disorders in Bangladesh. We have performed an investigation among 360 patients with Hb E/β-thalassemia to understand the heterogeneity in thalassemia severity among Bangladeshi patients. The analysis revealed that one of the common mutations CD26 (G>A) is found with two rare mutations HBB: c.-79A>G (-29A>G) and HBB: c.45_46insG (CD14/15 (+G)) in two patients individually which are not prevalent in geographically adjacent populations. Among these two rare mutations, -29A>G is located at the ‘TATA’ box region of the promoter sequence regulating transcription initiation and CD14/15 (+G) leads to a premature stop codon. We performed transcription factor binding site prediction analysis and found that ‘AP-1’, ‘c-Jun’, and ‘kr’ transcription factors bind at the ‘TATA’ box region. From this analysis, we can predict that -29A>G mutation can alter the level of HBB transcription whereas the CD14/15 (+G) mutation causes a truncated (and possibly non-functional) HBB protein. Aligned with such assumption, it was observed from patients’ medical history that, the patient who had CD14/15 (+G) and CD26 (G>A) mutations was severely blood transfusion-dependent whereas the patient carrying -29A>G and CD26 (G>A) mutations was moderately transfusion dependent. The comprehensive analysis of the mutations offers crucial insights and approaches for enhanced management of thalassemia among the Bangladeshi population. Bioresearch Commu. 10(1): 1442-1448, 2024 (January)

29 October 2021 in Asia Pacific Journal of Public Health
Verified
Journal Article
Closed access
PDF file
FAFaruq Abdulla
Faruq Abdulla
MAMustak Ayub
Mustak Ayub

28 July 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMd Abdul Aziz
Md Abdul Aziz
MAMustak Ayub
Mustak Ayub
WKWaqar Ahmed Khan
Waqar Ahmed Khan
SYSabina Yeasmin
Sabina Yeasmin
Haemoglobin E β-thalassemia (Hb Eβ-thal), characterized by the presence of codon 26 (G > A), HBB :c.79G > A mutation with another pathogenic variant is a common blood disorder in South-Asia, especially in Bangladesh. The disorder can range from mild and asymptomatic anemia to life-threatening forms. Here, we performed molecular analysis to understand how mutations in the HBB gene and the XmnI polymorphism influence the severity and transfusion requirements in patients with Hb Eβ-thalassemia. This study found that individuals with the codon 16 (-C), HBB :c.51delC mutation required regular blood transfusions, whereas those with the codon 30 (G > C), HBB :c.92G > C mutation had the lowest transfusion dependency, at only 6.7%. Patients with codon 30 (G > C), HBB :c.92G > C mutation had the highest response to hydroxyurea therapy (76.7% ( n = 23)), while patients with codon 16 (-C), HBB :c.51delC mutations had the lowest response (0% ( n = 14)). The codon 16 (-C), HBB :c.51delC mutation was associated with the lowest mean HbF level (24.8%, SD = 7.7), whereas the codon 30 (G > C), HBB :c.92G > C mutation was associated with the highest mean HbF level (41.9%, SD = 16.10). Regarding XmnI polymorphism, codon 16 (-C), HBB :c.51delC mutation was associated with the highest wild type (-/-) ( n = 11) genotype, while codon 30 (G > C), HBB :c.92G > C mutation was associated with the highest homozygous mutated (+/+) ( n = 11) and the least wild type (-/-) ( n = 4) of XmnI polymorphism genotype. This study provides clinically relevant insights into treatment strategies involving HU therapy and the management of Hb Eβ-thalassemia patients with codon 30 (G > C), HBB :c.92G > C and codon 16 (-C), HBB :c.51delC mutations.

27 October 2021 in Research Square
Verified
Preprint
Open access
PDF file
NPNahid Parvez
Nahid Parvez
LRLutfar Rahman
Lutfar Rahman
MRMostafizur Rahman
Mostafizur Rahman
MAMohammad Ali
Mohammad Ali
AUA.F.M Helal Uddin
A.F.M Helal Uddin
MAMustak Ayub
Mustak Ayub
BackgroundLymphedema–distichiasis syndrome (LD, OMIM 153400) is a hereditary primary lymphedema with autosomal dominant nature of inheritance and variable expression. LD is characterized by late childhood or pubertal onset of lower limb lymphedema and an aberrant second row of eyelashes (distichiasis) arising from the meibomian glands. Underlying molecular causes include mutations in the FOXC2 gene, which codes for a forkhead transcription factor involved in the development of the lymphatic and vascular system. ResultsIn this study, we report the first case of LD from Bangladesh with classical lymphedema–distichiasis syndrome who carries an eight-base-pair deletion in the FOXC2 -gene. ClinVar accession code for this deletion is RCV000007679.3. Although most other mutations of this gene are unique among different families, literature survey indicates this 8 bp deletion has been reported multiples times in independent studies for families from different geographical regions. ConclusionFOXC2 protein is 501 amino acid long. This deletion of 8 bp (ACGCCGCC) causes frameshift of codons after amino acid number 304. The frameshift creates an altered truncated protein with 154 newly amino acids after codon 304. We assume that these changes in the protein may affect its function contributing to the disease manifestations. Further research may confirm these assumptions.

16 May 2026 in Cancer Informatics
Verified
Journal Article
Open access
SDShuvra Dutta
Shuvra Dutta
SRS. M. Mahbubur Rashid
S. M. Mahbubur Rashid
MIMd. Shihabul Islam
Md. Shihabul Islam
SASk Farid Ahmed
Sk Farid Ahmed
MAMustak Ayub
Mustak Ayub
Background: Breast cancer (BC) is a leading cause of death among women. Pathogenic variations (PVs) in BRCA1 and BRCA2 genes increase the risk of hereditary and Triple-negative breast cancer (TNBC). Despite its great importance, NGS-based genetic testing of BRCA1 and BRCA2 in Bangladesh is out of reach of most patients because of its high cost. Objective: To overcome this challenge, this study explored whole genome databases (cBioPortal, gnomAD, dbSNP) to investigate whether sequencing selected exons in BRCA1 and BRCA2 genes may provide meaningful clinical interpretation of BC risk. Methods: Exons 4 and 16 of BRCA1 and exons 18, 23 and 25 of BRCA2 were selected for targeted analysis. According to the aforementioned databases, 10 and 21 mutations are pathogenic in the targeted regions of BRCA1 and BRCA2 respectively. To evaluate the presence or absence of these germline pathogenic variations (PV) in Bangladeshi BC patients, we collected blood samples from 13 subjects, among whom, 9 were diagnosed with BC, and 4 without cancerous tumors but with family history and breast lump. Results: Analysis of 13 patient samples revealed no PVs in the targeted regions. Within the BRCA1 gene, 5 of the 10 sites, and within the BRCA2 gene, 10 of the 21 sites associated with pathogenic variations were successfully sequenced and clearly interpretable. However, comparison with the reference sequence confirmed the absence of PVs in the targeted regions of both BRCA1 and BRCA2 . In silico analysis indicated that missense mutations are the predominant type of variation in both genes. Conclusion: This study, although limited by sample size, demonstrates that even exons enriched for pathogenic mutations may not be sufficiently representative for detecting PVs through targeted sequencing of BRCA1 and BRCA2 . Comprehensive sequencing of the full lengths of BRCA1 and BRCA2 may be necessary to ensure confident clinical interpretation in BC patients.